Dosing and administration for MENVEO
MENVEO is approved in two presentations: a 1-vial presentation for use in individuals 10 through 55 years of age and a 2-vial presentation for use in individuals 2 months through 55 years of age. Differences between the 1-vial and 2-vial presentations are summarized in this Dear Healthcare Provider Letter
MENVEO can help protect your younger and older adolescent patients
|MENVEO Dosing for Younger and Older Adolescents1|
|Primary Vaccination||Booster Vaccination|
|Single dose in adolescents and adults aged 10 through 55 years||Single booster dose may be administered to individuals 15 through 55 years of age who are at continued risk of meningococcal disease, at least 4 years after a prior dose of a MenACWY vaccine|
Consider MENVEO 2-vial presentation for your at-risk patients as young as 2 months of age
|MENVEO 2-Vial Presentation Dosing for Infants1|
|2 Months of Age||7 Months Through 23 Months of Age|
|4-dose series with a single dose (0.5 mL) at 2, 4, 6, and 12 months of age||2-dose series (0.5 mL each) with the second dose administered in the second year of life, at least 3 months after the first dose|
Reconstitution for MENVEO 2-vial presentation
INVERT the vial and shake well until powder is completely dissolved.
MenACWY=meningococcal serogroups A, C, W, Y.